Peter B. Corr, Chairman of ADC Managing and Therapeutics General Partner of Auven Therapeutics, said: Having the technology platform to build up novel ADCs against essential cancer targets and transform health care outcomes for sufferers is a critical component of what we are building at ADC Therapeutics. We are pleased to established this exclusive romantic relationship with the outstanding group in Dr. Bander's laboratories in Weill-Cornell. Financial terms were not remain and disclosed confidential.. ADC Therapeutics, BZL Biologics signal licensing offer for antibody against PSMA-positive prostate cancers ADC Therapeutics Sarl, a portfolio business of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody medication conjugates , and BZL Biologics LLC, of NY, today announced a special licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.for advancement in China for the treating iron insufficiency anemia in adult patients with chronic kidney disease . Feraheme was approved on June 30, 2009 by the U.S. Food and Medication Administration for the same indication that 3SBio is seeking authorization in China and launched commercially in the U.S. In July 2009 by AMAG. As previously announced, 3SBio has distinctive rights to develop and commercialize Feraheme in China. Once approved by the SFDA, 3SBio will commence a multi-middle randomized efficacy and safety study in China with approximately 200 CKD patients, measuring the mean change in hemoglobin from baseline at Day 35 after first dosage. Dr. Jing Lou, CEO of 3SBio responses: We are pleased with the timely submission of the Feraheme scientific trial software to the SFDA in China, representing a major milestone and our commitment to getting this innovative therapy to Chinese CKD individuals in need.